News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference

Benzinga

By Meg Flippin, Benzinga Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders including dementia with Lewy bodies (DLB), had the opportunity to raise awareness about its experimental drug zervimesine (CT1812) when the company presented trial results in a podium presentation at the International Lewy Body Dementia Conference (ILBDC). The eighth International Lewy Body Dementia Conference, held in Amsterdam last week, drew an international audience of advocates, scientists and physicians looking for ways to fight this debilitating disease. Zervimesine is an experimental, orally delivered small molecule oligomer antagonist designed to treat this progressive form of dementia. Cognition Therapeutics recently reported positive topline results of its exploratory phase 2 SHIMMER study for the drug, announcing zervimesine produced strong therapeutic responses across behavioral, functional, cognitive and movement measures in patients with DLB. “Older adults with DLB are often placed in care facilities not because of memory issues, but due to the severity of neuropsychiatric or motor symptoms that overwhelm their caregivers,” said James E. Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, who was the study director for SHIMMER. “Patients on zervimesine had fewer cognitive fluctuations and showed better motor control than placebo-treated patients. The results from this exploratory phase 2 trial demonstrated zervimesine could have a meaningful, positive impact on DLB patients across multiple measures of cognitive, behavioral, movement and functional performance, potentially enabling people with DLB to live at home with the assistance of their care partners.” DLB Drug Holds Promise DLB is a progressive form of dementia characterized by symptoms that fluctuate in severity and can be difficult to diagnose early. It can cause people to have hallucinations, delusions and anxiety as well as cognitive declines that impair their thinking and reasoning. It can cause uncontrollable changes in alertness, sleep disruptions, tremors and slow movement. DLB impacts about 1.4 million people in the U.S. and is the costliest form of dementia. The double-blind, placebo-controlled phase 2 SHIMMER study had 130 adults enrolled who were evenly divided into groups that received either a placebo or a daily dose of zervimesine for six months. Cognition Therapeutics reported the study met its primary endpoint of safety and tolerability. As presented at ILBDC, zervimesine-treated DLB patients scored an average of 86% better than placebo-treated patients on the neuropsychiatric inventory (NPI) A-L at the end of the study. This tool describes the frequency and severity of 12 separate behavioral symptoms. The impact on the NPI scale in the SHIMMER trial means that patients receiving zervimesine had fewer or less severe hallucinations and delusions and less anxiety and agitation than placebo-treated patients, the company noted. These symptoms are a hallmark of DLB and can be debilitating for patients. The improvement in these behavioral symptoms was measured not only for patients but also their care partners, who reported improvements in their levels of distress caused by these symptoms. Patients, Caregivers Benefit From Zervimesine Patients who received zervimesine also preserved 52% more of their ability to care for themselves, measured by the activities of daily living (ADCS-ADL) scale, compared to those taking the placebo. Cognition said this was likely due to the improvements in behavioral symptoms as well as a 91% reduction in cognitive fluctuations in zervimesine-treated patients. Cognitive fluctuations are another hallmark of DLB and are described as a non-responsive state that can occur suddenly and last for hours. The person experiencing the fluctuation may or may not be aware that it is happening. On top of all that, the company said that based on trial results, zervimesine treatment allowed patients to maintain 62% better motor function – including gait, balance and tremors – than those on the placebo. “Dr. Galvin’s presentation is an important opportunity to educate an international audience of advocates, scientists and physicians about the impressive efficacy signals that were observed in participants treated with zervimesine (CT1812),” said Anthony O. Caggiano, MD, PhD, Cognition’s CMO and head of R&D. “The improvement we observed across behavioral, cognitive, functional and motor symptoms in zervimesine-treated participants suggest a broad and meaningful impact on their daily lives. These results reinforce zervimesine’s potential to address the complex and debilitating symptoms of this disease.” Featured photo by Pawel Czerwinski on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2025 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

New Prostate Cancer Hope? Bayer-Funded Phase 2 Study To Test Combination Of RedHill's Opaganib And Bayer’s Darolutamide, To Overcome Androgen Resistance

Benzinga

By Meg Flippin Benzinga It is often said that, “Prostate cancer is the cancer you die with, not because of,” but according to RedHill Biopharma (NASDAQ: RDHL), based on data published in Frontiers in Public Health, around 400,000 men a year worldwide would probably disagree with that statement. With global prevalence set to double to 2.9 million cases a year by 2040, early detection of prostate cancer (PC) often leads to a favorable outcome, with many patients thankfully responding very well to treatment. However, RedHill says around 20% of men with prostate cancer will either not respond to the current standard of care androgen receptor signaling inhibitor therapies, or will become resistant to these drugs, and will advance to a point where current treatments offer no additional hope. Patients who develop what is known as metastatic castrate-resistant prostate cancer (mCRPC) and are not responsive to hormone therapy, are left with virtually no treatment options. Invariably, they will go on to die from their cancer, the company says. But potentially, there may be some hope thanks to a clinical collaboration, funded by Bayer AG (ETR: BAYN), a large global pharma company, and the Ramsay Hospital Foundation, between RedHill, Bayer and Australian cancer researchers. The collaboration will involve a study to test the potentially enhancing effect of RedHill’s treatment, opaganib, in combination with Bayer’s darolutamide, in overcoming resistance to androgen receptor pathway inhibition (ARPI) treatment. First approved in 2021, and now approved in more than 80 countries, Bayer’s darolutamide was the fastest -growing androgen receptor blocker in the U.S. and continues to enjoy a strong growth trajectory, with sales in 2024 almost doubling 2023’s numbers. With more positive clinical data unveiled last year, and the expectation of additional approvals in more markets and across more prostate cancer indications, Bayer expects sales of darolutamide to peak at around $3 billion a year – potentially making it one of the most successful drugs in the prostate cancer space. Treating Advanced Stage Prostate Cancer A major driver of prostate cancer is androgen receptor signaling, which is why using chemical castration or androgen deprivation therapy has become a standard care treatment. Unfortunately, patients with advanced PC, and in particular those who have already progressed to mCRPC, become or are resistant to it, RedHill reports. However, the company also notes that according to the results of laboratory studies involving leading ARPI therapy, darolutamide, there may be a way to boost sensitivity to therapy and potentially overcome resistance – with the addition of another drug, opaganib. Opaganib is RedHill’s first-in-class, novel and orally-administered selective inhibitor of sphingosine kinase-2 (SPHK2). Opaganib has shown anti-inflammatory, anti-cancer and antiviral activity, and its mechanism of action, being an intracellular sphingolipid pathway modifier with multiple cell-level functions, including potential inhibition of tumor growth, supports the hypothesis that it could boost the efficacy of darolutamide, the company says. Cancer cells can block a cell-level process called apoptosis (programmed cell death), preventing the body from getting rid of unneeded or abnormal/unhealthy cells – a critical weapon our bodies use in fighting the spread of cancer. RedHill says prior research has shown that opaganib enhances androgen receptor signaling inhibitor efficacy in vitro through simultaneous inhibition of three sphingolipid-metabolizing enzymes in human cells (SPHK2, DES1 and GCS) and may potentially provide the key to overcoming darolutamide resistance in men with mCRPC. The company says, it is opaganib’s potential ability to induce metabolic stress in tumor cells that may be at the heart of the hope this study could bring people with mCRPC. With the prevalence of prostate cancer set to double over the next 15 years and only a 28% five-year relative survival rate in people with stage 4 prostate cancer, there is a significant need for new approaches in treating mCRPC patients. Pinpointing Who Is Most Likely To Benefit Patients with a poor prognosis due to ARPI resistance are most likely to benefit from an opaganib/darolutamide combination treatment approach, and identifying these patients will be key, RedHill says. As such, another innovation, a companion lipid biomarker test called PCPro, will be used to identify the right patients as part of the study. “Men with mCRPC have few treatment options available to them, and those positive for the PCPro marker of ARPI-resistance seem to have a particularly poor prognosis,” said Dr. Mark Levitt, RedHill’s chief scientific officer. “If the addition of opaganib can reduce the resistance to darolutamide therapy, this would represent a significant breakthrough in improving the ability to manage advanced treatment-resistant mCRPC for improved outcomes.” Phase 2 Trial Launching Soon Supported by Bayer and the Ramsay Hospital Foundation, the potential effectiveness of the opaganib/darolutamide combination will be put to the test in an 80-patient phase 2 clinical trial, due to start shortly. The placebo-controlled, randomized phase 2 study will evaluate the effect of opaganib, in combination with Bayer’s darolutamide, in overcoming resistance to standard-of-care androgen receptor pathway inhibition (ARPI) treatment in men with mCRPC who have not already received the newer AR signaling inhibitors such as enzalutamide, apalutamide, darolutamide or abiraterone. A primary endpoint of improved 12-month radiographic progression-free survival (rPFS) will be the key assessment of success in the study, but several secondary and exploratory endpoints will also be evaluated, the company noted. “The approach of developing therapeutic combinations and the companion lipid biomarker, PCPro, in parallel, is unique in metabolic targeting in metastatic prostate cancer, and this exciting study may provide proof of concept by testing the ability of sphingosine kinase-2 (SPHK2) inhibitors, such as opaganib, to overcome resistance to ARPI treatment,” said Professor Lisa Horvath, world-renowned prostate cancer researcher and chief clinical officer and director of research at Chris O’Brien Lifehouse. Sydney’s Chris O’Brien Lifehouse is a not-for-profit, comprehensive cancer hospital, that also developed the concept of using a PCPro marker-directed opaganib/darolutamide combination approach. “Cancer cells may block apoptosis (programmed cell death), an important cell-level process designed to help the body get rid of unneeded or abnormal/unhealthy cells – critical in fighting the spread of cancer,” Horvath said. Trial Partners Pedigree Australia is a global leader in the field, and the driving force behind this collaboration is Horvath and her team from Chris O’Brien Lifehouse. The trial will be led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd. (ANZUP), a leading Cancer Cooperative Trials Group specializing in conducting studies for prostate, bladder, kidney, testicular and penile cancers. Prostate cancer diagnoses are expected to surge as the population around the world ages, and fighting this deadly disease just took on new urgency. If this combination of RedHill’s opaganib and darolutamide proves itself in this study, it may go on to play an important role in helping to improve the prospects for hundreds of thousands of men with advanced prostate cancer who currently have a very bleak outlook. Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 05, 2025 08:35 AM Eastern Standard Time

Image
Article thumbnail News Release

PayMedix and XO Health Announce Strategic Partnership that Redefines Healthcare Financing and Payments

PayMedix

PayMedix, a leading healthcare financing and payments solutions provider, and XO Health, a pioneering value-based care and benefits platform dedicated to transforming healthcare for self-insured employers, today announced a strategic partnership that expands access to PayMedix’s healthcare financing solution to XO Health’s extensive network of self-insured employers, TPAs, and value-based providers. XO Health members nationally will benefit from PayMedix’s interest-free payment plans that work for their unique financial situations and cover all in-network medical bills, up to their out-of-pocket maximum. All participating providers will benefit from prompt payment for both member and plan-pay portions of their claims. The partnership will help reduce costs and administrative inefficiencies. “Our mission has always been to improve people’s ability to access and afford healthcare when they need it, while simultaneously removing the complexity and administrative burden of bill collection and processing from providers, and simplifying billing for patients,” said Tom Policelli, CEO of PayMedix. “Our partnership with XO Health aligns with this mission. We’re disrupting the way people access and pay for healthcare together.” PayMedix creates a holistic healthcare payment experience and simplifies the process of billing for all parties involved – patients, providers, employers, and TPAs. Patients receive the benefit of flexible repayment plans that remove financial barriers to care. Providers benefit from prompt payment and a reduction in administrative costs. Employers benefit by improving their employees’ well-being, reinvigorating their benefits, and enhancing their employees’ medical experience through simplified statements. The result is employees across the credit spectrum access care earlier and more often, improving health equity and reducing overall cost. XO Health is redefining how healthcare is delivered and paid for by dramatically expanding access to value-based care with new advanced payment models and a modern tech platform that completely rewires health plan operations, delivering a better healthcare experience to self-insured employers, level-funded plans and TPAs. Key features of XO Health’s health plans include: provider networks built on trust and autonomy; secure, real-time data, and analytics powered by a cloud-native data and generative AI; a proprietary pricing and payments engine that enables the creation, pricing, and tracking of “smart care packages” in real time with full transparency into claims, pricing, and payments; and integrated member and provider tools that provide high-touch frictionless transactions and interactions for both plan members and providers. “At XO Health, we believe that bringing trust, transparency, and common sense to healthcare requires foundational changes to how we pay for care,” said Swati Mathai, Co-founder and CEO, XO Health. “Our partnership with PayMedix enables us to deliver on this vision by offering a more straightforward approach to billing that prioritizes simplicity and fairness for both members and providers. By eliminating meaningless complexities of healthcare payments, it allows providers and members to focus on what’s truly important, better care and better health.” About PayMedix PayMedix is the only company solving the problem of high out-of-pocket costs for all parties involved -- providers, patients, employers, and TPAs. PayMedix is changing how people access, use, and pay for healthcare by guaranteeing payments to providers and providing financing for all patients. PayMedix has processed more than $5 billion in medical payments for hospital systems and physician practices and can be implemented in conjunction with any network. About XO Health XO Health is a groundbreaking value-based care and benefits platform with a mission to bring trust, transparency, and common sense back to healthcare. Built on a foundation of real-time data and analytics and offering a broad solution set, the XO Health platform powers excellence across the entire healthcare ecosystem. With an unparalleled team of experienced leaders from diverse domains, XO Health is uniquely positioned to disrupt the healthcare landscape and deliver the transformative change the industry deserves. To learn more, please visit www.xohealth.com. Contact Details Brodeur Partners Sam LeCompte +1 603-660-9407 slecompte@brodeur.com PayMedix/TempoPay Hattie Ninteau hninteau@hps.md Company Website https://paymedix.com/

February 04, 2025 08:00 AM Eastern Standard Time

Article thumbnail News Release

Flash Names Jim Zeitunian Chief Technology Officer

Flash

Flash, the leader in parking and mobility technology, today announced the hiring of Jim Zeitunian as Chief Technology Officer (CTO). Over his decades-long career, Zeitunian has led the transformation of hardware and software firms into AI-forward technology innovators. As CTO of Flash, he will drive innovation and advancement of the digital parking ecosystem powering Flash’s parking management platform. "Now is a pivotal time in parking and mobility innovation, and Jim's track record of modernizing legacy industries through AI and cloud technologies aligns perfectly with Flash's vision," said Dan Sharplin, Flash's CEO and Chairman. "His expertise in scaling AI platforms will accelerate our transformation of the parking experience, from expanding our AI-enabled Vision camera network to deepening integrations with consumer apps like ParkMobile. Jim's leadership will be instrumental in building the intelligent mobility infrastructure of tomorrow." Zeitunian joins Flash with a distinguished career in technology leadership, including most recently as CTO of Powerfleet, where he transitioned a traditional fleet management business into a data-driven SaaS powerhouse. Earlier in his career, he developed enterprise SaaS platforms at Coupa Software and Thomson Reuters, gaining unique insight into scaling complex technology ecosystems for Fortune 500 businesses. "The parking industry is ready for an AI-driven revolution, and as a pioneer in parking and mobility technology, Flash has positioned itself to lead it," said Zeitunian. "We’re creating an intelligent parking network that will fundamentally change how people and vehicles move through urban spaces. The opportunity to join Flash's talented team to scale this vision globally is incredibly exciting." In the CTO role, Zeitunian assumes leadership of Flash's global engineering, product management and design, and quality assurance teams and reports to Flash president Chris Donus. Priorities include expanding Flash's AI capabilities across its product portfolio, scaling the company's cloud-based operating system to support growing transaction volumes, and accelerating the integration of parking, EV charging, and mobility services into a unified digital experience. About Flash Flash is a pioneering technology company bringing seamless parking and EV charging experiences to drivers through a first-of-its-kind digital ecosystem. Flash’s platform connects reservable parking and charging in the apps drivers use every day with garage, surface lot, event, and valet parking locations — connected and controlled via a cloud-based operating system with unrivaled intelligence. Customer-obsessed brands partner with Flash to deliver digital, easy-to-use, reliable, and increasingly frictionless experiences to drivers eager to pay for a solution that eliminates wasted time, excess emissions, and stress from driving. The solution has arrived. Visit www.flashparking.com to learn more. Contact Details Ray Young +1 512-694-6097 ray@razorsharppr.com Company Website https://www.flashparking.com/

February 03, 2025 12:00 PM Central Standard Time

Article thumbnail News Release

CAREABOUT HEALTH APPOINTS TWO NEW C-SUITE EXECUTIVES

CareAbout Health

CareAbout Health, a provider of management, resources, value-add services, technology and other support to a portfolio of medical groups and healthcare focused companies, announced today the appointment of two C-suite executives. Danielle Webb was named chief operating officer and Scott Robbins was appointed chief people officer. In her new role, Webb, will be responsible for overseeing CareAbout’s daily operations and optimizing processes across the national umbrella entities, which fall within the MSO. She will also drive strategic initiatives around enhancing patient care, improving operational efficiencies and achieving long-term growth. Prior to this appointment, Webb served as chief operating officer of Medical Specialists of the Palm Beaches (MSPB), a leading primary care-focused, multi-specialty physician group practice in South Florida. In this capacity, she headed day-to-day operations and was instrumental in optimizing MSPB’s performance and growth. Robbins, with two decades of healthcare human resources expertise, will lead and manage CareAbout’s centralized human resources function, including benefits, recruitment, employee engagement and other key tasks critical to its talent and workforce. Before joining CareAbout, Robbins spent five years serving as chief people officer at WellBe Senior Medical, a geriatric in-home healthcare provider, where he played a pivotal role in supporting Company’s growth by expanding the team from nine employees to 1,000+. His extensive experience includes establishing and enhancing HR frameworks for a range of entities, including start-ups, for-profit and non-profit companies and community-based healthcare organizations. “Danielle and Scott both have extensive, proven track records in their respective niches within the healthcare services arena. They each have demonstrated exemplary leadership and operational expertise, making them excellent candidates for these positions,” said Dr. Nedal Shami, chief executive officer at CareAbout Health. “As we grow CareAbout’s managed shared services (MSO) model, we need the right team in place to lead us to our goals of ensuring the delivery of the highest quality care while leveraging the benefits of unified, shared services across our medical group practices. Daneille and Scott round out that team, and we look to the contributions they will make in their new roles,” Dr. Shami stated. About CareAbout Health New York, NY-based CareAbout Health provides management, resources, value-add services, technology, and other support to a portfolio of medical groups and healthcare focused companies. The management services organization focuses on empowering providers, improving patient outcomes and advancing value-based care models, delivering scalable, efficient solutions while maintaining local medical care autonomy in key geographic markets. For more information, please visit www.careabout.com. Contact Details PAIRELATIONS Susan J. Turkell +1 303-518-7100 sturkell@pairelations.com Company Website https://careabout.com/

February 03, 2025 08:00 AM Eastern Standard Time

Image
Article thumbnail News Release

Wire Industries Partners with Birches Health to Create Safer, More Responsible Gaming Environment

WagerWire

Wire Industries, Inc., a technology and media company that owns and operates sports betting marketplace WagerWire, announced today that it has partnered with Birches Health, a leading behavioral healthcare company that specializes in the online and confidential prevention and treatment of problem gambling-related challenges. This partnership complements the work Wire Industries has already done to promote responsible gaming by redefining what it means for bettors to have control over their entertainment time participating in real-money gaming and daily fantasy sports. Through this partnership, Wire Industries will propel awareness of responsible gaming and increase bettors’ access to important guidance and tools to ensure they are better informed and aware of the signs of problem gambling and prepared to take steps to address it if they see themselves or others exhibiting those signs. Wire Industries and Birches Health will work together to create clinical materials tailored to the needs of the modern bettor. In addition, Birches Health clinicians will appear on Wire Industries Spaces interviews held live on X.com, Birches Health content will be integrated across the WagerWire app and specific Birches Health and WagerWire co-created resources and tools will live across each partner’s website. “Wire Industries was created with the sole purpose to empower bettors and create an environment of responsible gaming,” said Wire Industries CEO Zach Doctor. “By working with Birches Health, we join ourselves with another innovative company in the industry that is also doing whatever they can to create more awareness, tools and resources for the bettor all while reinforcing our commitment to responsible gaming. We hope others in the industry see this innovation as a way to better the modern bettor and follow suit.” Birches Health is a modern digital healthcare company specializing in the prevention and treatment of behavioral addictions, with a primary focus on gambling disorder and related mental health issues in the United States. Utilizing a three-tiered strategic approach—education, engagement, and treatment—Birches Health offers free online learning modules, self-assessments, tools, and educational content to promote Responsible Gaming and prevent problem behaviors. For individuals in need, personalized treatment plans are crafted and led by licensed, specialized behavioral health clinicians available 24/7. Dedicated to providing convenient and comprehensive care, Birches Health empowers individuals to address behavioral health challenges effectively. “We applaud WagerWire and their team for a focus on making resources and education available and empowering their users to make healthier lifestyle choices.,” said Elliott Rapaport, Founder of Birches Health. “Partnering with Wire Industries to make sure that treatment options through WagerWire, FantasyWire and its other platforms are available to those who may need them creates a culture of sustainable play for all participants.” As part of this initiative, WagerWire and Birches Health are also exploring opportunities to integrate AI-driven tools and personalized support pathways into the WagerWire platform, further enhancing user education and care accessibility. This partnership will also further Wire Industries as an innovative, forward-thinking disruptor in all aspects associated with the gaming world. About Wire Industries Wire Industries Inc was founded with the mission to bring a more efficient, open, and entertaining market to real money gaming of all types, unlocking value for the entire ecosystem. The company was established in 2021 and owns and operates Wire Technologies and Wire Media Group. Wire Technologies is the company’s marketplace division including WagerWire, FantasyWire, PonyWire and ContestWire, while Wire Media Group operates their media network and affiliate marketing division. You can download their flagship product WagerWire in the Apple App Store and Google Play, and find them @WagerWire on Twitter/X, TikTok and LinkedIn, or @WagerWireLive on Instagram. Wire Industries is dedicated to providing a responsible gaming environment. If you think you or someone you know may have a gambling problem, resources are available. Call 1-800-GAMBLER or reach out to their Chief Responsibly Officer Carolina Young directly at live@wagerwire.com. About Birches Health Birches Health provides modern, clinician-led solutions for Responsible Gaming and Problem Gambling care covered by insurance. For more information, visit Birches Health at bircheshealth.com or email partnerships@bircheshealth.com. Contact Details Sterling Randle srandle@hotpaperlantern.com

January 30, 2025 09:01 AM Eastern Standard Time

Image
Article thumbnail News Release

IntusCare Celebrates Milestone Year Building Momentum for 2025

IntusCare

IntusCare, a technology leader in the PACE market, celebrated a transformative year in its offerings for PACE (Programs of All-Inclusive Care for the Elderly), underscoring its commitment to supporting value-based care (VBC) models that serve complex senior populations. The company looks to build on the significant momentum in 2025. IntusCare starts the year with additional funding, having recently announced the company raised $11.5 million in a strategic follow-on financing round, bringing total funding to over $27 million. This infusion of capital will fuel the launch of CareHub, a comprehensive care management platform, and support the expansion of IntusCare’s existing suite of Revenue Integrity, Population Health, and Utilization Management solutions. Additionally, the company plans to accelerate its artificial intelligence research, aiming to enhance user experiences for healthcare providers and staff. Notably in 2024, the company announced the launch of two new products and one new service, all specifically designed for PACE. CareHub: The first PACE-specific EMR and practice management system for workflows to manage the VBC model, revolutionizing how interdisciplinary care teams, quality, and compliance managers care for older adults with complex healthcare needs. Intus Revenue Integrity System (IRIS): The first real-time, data-driven risk adjustment system designed specifically for PACE and VBC organizations. IRIS is designed to support PACE and VBC clinical, financial, compliance, and leadership teams to optimize workflows for consistent risk adjustment results. Delegated Utilization Management (UM) Service for PACE: The availability of fractionally-staffed Integrated Care Services (ICS) clinicians and nurses who optimize utilization management for organizations. “This year has been exciting in terms of building a foundation and the momentum to better serve our customers through technology and the expertise we bring to the industry,” said Robbie Felton, CEO and co-founder of IntusCare. “Initially when we started this company during college, we began as a data provider for PACE programs for better care decisions empowered by population health analytics. Now, we’ve grown in scope with delegated services, risk adjustment, and an EMR and practice management system, providing more value to our clients who are empowered to provide even better care for their complex, senior patients.” Much of IntusCare’s growth in scope took place within the last year, propelled by deep partnerships with their customers who shared their needs with the company. The vision for CareHub emerged when customers shared pain points such as reducing staff documentation and administrative burden, integrating disparate data systems, and enabling actionable workflows for interdisciplinary care teams. “Ultimately, we want to be the place where all value-based care organizations that manage risk for complex care come to do their work. CareHub is a key foundation of the ultimate operating system that we're looking to build for the space and community,” said Evan Jackson, co-founder and Chief Operating Officer for IntusCare. Strategic Partnerships Over the last year, IntusCare grew its strategic partnerships, including the addition of new PACE programs as clients along with alliances with other technology companies to improve offerings to customers. IntusCare now serves 70+ PACE organizations across the country, adding 33 new partners in 2024, an increase of ~90% over 2023. This growth is driven by our commitment to both grow alongside our existing partners and expand throughout PACE with the aligned goal of empowering high quality participant care. In addition, IntusCare is breaking down industry silos by prioritizing data access and interoperability through strategic partnerships with leading technology companies. This approach ensures the delivery of impactful, integrated solutions that better serve its customers. An example of how IntusCare is prioritizing interoperability with PACE organizations is through its collaboration with MedVision for seamless data integration, improved care coordination, regulatory and compliance support, and operational and financial efficiencies. Another partnership with Grane Rx will allow their pharmacy solutions to integrate with CareHub supporting medication safety, streamlined workflows, and advanced ePrescribing within the platform for PACE. Thought Leadership Education Providing software solutions is not enough within the complex healthcare environment, including some of the intricacies of PACE. IntusCare used its expertise and connections to support thought leadership educational opportunities to benefit the PACE ecosystem. Chief Population Health Officer Laura Ferrara, an experienced PACE leader, presented at several PACE organization conferences and meetings throughout the year, including a PACE Basics workshop at the National PACE Association’s annual conference in October. In November, IntusCare hosted a virtual conversation on “PACE and the Future of Healthcare Data Interoperability” with leading guests within healthcare and the PACE community. IntusCare CEO Robbie Felton moderated the discussion with Shawn Bloom, CEO and president of the National PACE Association (NPA); Dr. David Feinberg, Chairman of Oracle Health; and Stephanie Rock, Vice President of Product & Client Delivery at IntusCare. Team Growth In order to expand its software and services options, IntusCare strategically grew its team, including the addition of key leadership positions. Bharath Kakarla joined as the Senior Vice President of Engineering to lead the technology team, collaborating closely with product and design counterparts to ensure that IntusCare's products and services align seamlessly with customer needs. Stephanie Rock joined as Senior Vice President of Product and Client Delivery, leading the product and design teams to ensure the company meets the needs of IntusCare’s current and future partners. For more information and to schedule a demo or consultation, reach out through IntusCare’s website. About IntusCare ‍ IntusCare develops innovative predictive analytics platforms aimed at improving geriatric care outcomes. Founded in 2019 by Brown University undergraduate students, IntusCare empowers geriatric care providers to deliver more effective patient management and treatment for dual-eligible seniors – some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Visit our website to learn more intuscare.com. Contact Details Alison Matthiessen +1 401-490-9700 intuscare@svmpr.com Company Website https://intuscare.com/

January 29, 2025 10:00 AM Eastern Standard Time

Article thumbnail News Release

Market Alert: PESG Releases New Report Highlighting Silexion Therapeutics as an Emerging Leader in the Multi-Billion Dollar Precision Oncology Industry

Global Markets News

PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN) * continues to strengthen its position in the precision oncology landscape with breakthrough preclinical data validating systemic administration of SIL-204, potentially opening new frontiers in treating KRAS-driven cancers. This development comes amid increasing industry appetite for innovative oncology assets, exemplified by recent multi-billion dollar acquisitions. Silexion's latest preclinical findings mark a significant advancement in RNAi therapeutics, with data showing 50% tumor growth reduction and complete necrosis in half of treated tumors after 30 days, sustained therapeutic levels for over 56 days from a single administration, and broad coverage of key KRAS mutations (G12D, G12V, G12R, Q61H, and G13D). These results build upon previous successes, including promising synergy with first-line chemotherapies and the strategic collaboration with Evonik for advanced PLGA microparticle formulation. The precision oncology landscape has witnessed unprecedented consolidation, with Pfizer's $43 billion acquisition of Seagen and AbbVie's $10.1 billion purchase of Immunogen exemplifying the industry's willingness to invest heavily in innovative cancer therapeutics. These transactions reflect a broader industry shift toward precision medicine, particularly in oncology, where targeted therapies command significant premiums. Silexion's emergence as a potentially compelling player stems from its differentiated RNAi approach to targeting one of oncology's most challenging problems, offering broader applicability across multiple KRAS mutations compared to competitors' small molecule inhibitors. The first-generation LODER™ platform has already demonstrated promising Phase 2 results, while the next-generation SIL-204 advances toward clinical trials with successful validation of systemic administration. Notable industry analysts seem to have taken notice, with Maxim Group initiating coverage with a "strong buy" recommendation in November 2024 and an updated price target of $9. As Silexion advances toward clinical trials with SIL-204 and explores expanded development strategies, several key catalysts may lie ahead and could be worth watching closely, including metastasis impact studies, advancement towards next phases of trials, data from additional indications, potential strategic partnerships, and more positioning the company uniquely in the precision oncology landscape at a time when the industry actively seeks innovative solutions for challenging cancers. Click here to Subscribe for more updates like this Read out Previous update regarding Silexion Therapeutics Read out Previous update regarding Silexion Therapeutics >> We Encourage you to read the source news from Silexion: Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (*)Important Disclaimers & Disclosures: This report is for informational purposes only and should not be considered financial or investment advice. The author is not a registered financial or investment advisor nor does he hold any type of license or engage in any activity that would require one. The content may include forward-looking statements and opinions that may not materialize. Investors should conduct their own due diligence and consult with a qualified investment professional before making any investment decisions. This report was produced by ‘PESG Research’, a content brand which is part of the Wall Street Wire network, a digital coverage and news distribution subscription service and platform operated for commercial, promotional and investor relations purposes. This report contains advertising/promotional content relating to Silexion Therapeutics. Please review our detailed disclosure and disclaimer linked below which details the subscription fees the operators of PESG and the network of brands it is a part of received from Silexion Therapeutics and other customers for coverage, distribution and news promotion services, in accordance with Section 17(b) of the Securities Act. Please review the full disclaimers and disclosures this report is subject to: https://redditwire.com/terms. Contact Details Wall Street Wire Reports Desk* ronald@futuremarketsresearch.com

January 29, 2025 09:24 AM Eastern Standard Time

Article thumbnail News Release

Centre for Neuro Skills Earns Accreditation in Applied Behavioral Analysis and Training at Three of its Locations

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in traumatic brain injury and stroke rehabilitation services, has been accredited by the Behavioral Health Center of Excellence (BHCOE) for demonstrating a commitment to the standards of excellence for applied behavior analysis services. The BHCOE Accreditation® distinguishes applied behavior analysis (ABA) therapy providers that demonstrate continuous improvement in applied behavior analysis and dedication. Three of CNS’ locations in Bakersfield and Los Angeles, California, and Irving, Texas have earned this accreditation and have been approved as training sites for behavior analysis students. Since 1980, Centre for Neuro Skills has treated thousands of people whose brain injury deficits include complex behavior challenges. Behavior analysts and therapists are trained in behavior skills, crisis prevention and management, and implementation of comprehensive, interdisciplinary rehabilitation programs. As an accredited training site, students and interns can learn from board-certified behavior analysts to help treat behavior problems. “We are thrilled that our behavior department and treatment program has been recognized as a standard of excellence,” said Chris Persel, Regional Director of Clinical Services and Director of Behavior Programming. “This accreditation opens up more opportunities for behavior analysis students and demonstrates the importance of providing behavioral analysis services to individuals facing a brain injury." *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

January 29, 2025 06:01 AM Pacific Standard Time

Image
12345 ... 290